A Novel PEGylated Block Copolymer in New Age Therapeutics for Alzheimer’s Disease

[1]  C. Das Mukhopadhyay,et al.  Functional amyloids: interrelationship with other amyloids and therapeutic assessment to treat neurodegenerative diseases , 2018, The International journal of neuroscience.

[2]  S. Chaudhury,et al.  Functional amyloids: interrelationship with other amyloids and therapeutic assessment to treat neurodegenerative diseases , 2018 .

[3]  Alzheimer’s Association.  2018 Alzheimer's disease facts and figures , 2018, Alzheimer's & Dementia.

[4]  R. Leblanc,et al.  The Investigation on Resorcinarenes towards either Inhibiting or Promoting Insulin Fibrillation. , 2017, Chemistry.

[5]  M. Rolandi,et al.  Suppression of Oligomer Formation and Formation of Non-Toxic Fibrils upon Addition of Mirror-Image Aβ42 to the Natural l-Enantiomer. , 2017, Angewandte Chemie.

[6]  S. Bachurin,et al.  Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends , 2017, Medicinal research reviews.

[7]  S. Chaudhury,et al.  Role of Curcumin in Treatment of Alzheimer Disease , 2017 .

[8]  Ren-Shyan Liu,et al.  An intranasally delivered peptide drug ameliorates cognitive decline in Alzheimer transgenic mice , 2017, EMBO molecular medicine.

[9]  Thomas Arnold,et al.  Self-Assembly and Anti-Amyloid Cytotoxicity Activity of Amyloid beta Peptide Derivatives , 2017, Scientific Reports.

[10]  Michele G. Sullivan,et al.  Alzheimer’s Candidate Drug Aducanumab Moves to Phase III , 2017 .

[11]  D. Khalsa,et al.  The Four Pillars of Alzheimer’s Prevention , 2017, Cerebrum : the Dana forum on brain science.

[12]  K. Chattopadhyay,et al.  Interaction of KMP-11 with Phospholipid Membranes and Its Implications in Leishmaniasis: Effects of Single Tryptophan Mutations and Cholesterol. , 2017, The journal of physical chemistry. B.

[13]  Hongda Wang,et al.  Reply to the 'Comment on "Magnetic-field-enabled resolution enhancement in super-resolution imaging"' by Bergmann et al., Physical Chemistry Chemical Physics, 2017, 19, DOI:10.1039/C6CP05108A. , 2017, Physical Chemistry, Chemical Physics - PCCP.

[14]  S. De Santis,et al.  PEGylated β-Sheet Breaker Peptides as Inhibitors of β-Amyloid Fibrillization. , 2017, ChemPlusChem.

[15]  K. Houk,et al.  A resorcinarene for inhibition of Aβ fibrillation† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c6sc04854d Click here for additional data file. , 2016, Chemical science.

[16]  S. Biswas,et al.  Tribbles Pseudokinase 3 Induces Both Apoptosis and Autophagy in Amyloid-β-induced Neuronal Death* , 2016, The Journal of Biological Chemistry.

[17]  M. Prince,et al.  World Alzheimer report 2016: improving healthcare for people living with dementia: coverage, quality and costs now and in the future , 2016 .

[18]  A. Rauk,et al.  Molecular dynamics studies of a β-sheet blocking peptide with the full-length amyloid beta peptide of Alzheimer’s disease , 2016 .

[19]  Suparna Sarkar-Banerjee,et al.  The Non-native Helical Intermediate State May Accumulate at Low pH in the Folding and Aggregation Landscape of the Intestinal Fatty Acid Binding Protein. , 2016, Biochemistry.

[20]  Sara Linse,et al.  Atomic Resolution Structure of Monomorphic Aβ42 Amyloid Fibrils. , 2016, Journal of the American Chemical Society.

[21]  V. Subramaniam,et al.  Two distinct β-sheet structures in Italian-mutant amyloid-beta fibrils: a potential link to different clinical phenotypes , 2015, Cellular and Molecular Life Sciences.

[22]  Xin-guo Jiang,et al.  Intranasal H102 Peptide-Loaded Liposomes for Brain Delivery to Treat Alzheimer’s Disease , 2015, Pharmaceutical Research.

[23]  Wenli Song,et al.  A Water-Soluble Conjugated Polymer with Pendant Disulfide Linkages to PEG Chains: A Highly Efficient Ratiometric Probe with Solubility-Induced Fluorescence Conversion for Thiol Detection , 2015 .

[24]  Michele Vendruscolo,et al.  The molecular chaperone Brichos breaks the catalytic cycle that generates toxic Aβ oligomers , 2015, Nature Structural &Molecular Biology.

[25]  Xiaogang Qu,et al.  Gold-nanoparticle-based multifunctional amyloid-β inhibitor against Alzheimer's disease. , 2015, Chemistry.

[26]  Xiaoyao Zheng,et al.  The potential use of H102 peptide-loaded dual-functional nanoparticles in the treatment of Alzheimer's disease. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[27]  Sonu Kumar,et al.  Controlled synthesis of β-sheet polymers based on side-chain amyloidogenic short peptide segments via RAFT polymerization , 2014 .

[28]  R. Swerdlow,et al.  The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives. , 2014, Biochimica et biophysica acta.

[29]  Kevin H. Chen,et al.  A Fibril-Like Assembly of Oligomers of a Peptide Derived from β-Amyloid , 2014, Journal of the American Chemical Society.

[30]  J. Cummings,et al.  Alzheimer’s disease drug-development pipeline: few candidates, frequent failures , 2014, Alzheimer's Research & Therapy.

[31]  P. Mecocci,et al.  Clinical trials and late‐stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014 , 2014, Journal of internal medicine.

[32]  F. Hane.  Are amyloid fibrils molecular spandrels? , 2013, FEBS letters.

[33]  X. Qu,et al.  Photodegradation of β-sheet amyloid fibrils associated with Alzheimer's disease by using polyoxometalates as photocatalysts. , 2013, Chemical communications.

[34]  U. Hansmann,et al.  The stability of cylindrin β‐barrel amyloid oligomer models—A molecular dynamics study , 2013, Proteins.

[35]  Guanghong Wei,et al.  Aβ(16-22) peptides can assemble into ordered β-barrels and bilayer β-sheets, while substitution of phenylalanine 19 by tryptophan increases the population of disordered aggregates. , 2013, The journal of physical chemistry. B.

[36]  Ashley I. Bush,et al.  Metal dyshomeostasis and oxidative stress in Alzheimer’s disease , 2013, Neurochemistry International.

[37]  Nicholas W. Smith,et al.  Dye-binding assays for evaluation of the effects of small molecule inhibitors on amyloid (aβ) self-assembly. , 2012, ACS chemical neuroscience.

[38]  Michael H. Hecht,et al.  A Novel Inhibitor of Amyloid β (Aβ) Peptide Aggregation , 2012, The Journal of Biological Chemistry.

[39]  S. Margel,et al.  Engineered polymer nanoparticles containing hydrophobic dipeptide for inhibition of amyloid-β fibrillation. , 2012, Biomacromolecules.

[40]  B. Strooper,et al.  The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes , 2012, Nature Neuroscience.

[41]  Inchan Kwon,et al.  A safe, blood-brain barrier permeable triphenylmethane dye inhibits amyloid-β neurotoxicity by generating nontoxic aggregates. , 2011, ACS chemical neuroscience.

[42]  David Eisenberg,et al.  Molecular basis for amyloid-β polymorphism , 2011, Proceedings of the National Academy of Sciences.

[43]  X. Qu,et al.  Polyoxometalates as inhibitors of the aggregation of amyloid β peptides associated with Alzheimer's disease. , 2011, Angewandte Chemie.

[44]  R. Mayeux,et al.  Epidemiology of Alzheimer disease , 2011, Nature Reviews Neurology.

[45]  G. Drochioiu,et al.  RAPID CHARACTERIZATION OF PEPTIDE SECONDARY STRUCTURE BY FT-IR SPECTROSCOPY , 2011 .

[46]  J. Carver,et al.  αB-Crystallin inhibits the cell toxicity associated with amyloid fibril formation by κ-casein and the amyloid-β peptide , 2010, Cell Stress and Chaperones.

[47]  Pierrick Bourgeat,et al.  Relationship between Atrophy and Beta-Amyloid Deposition in Normal Elderly, Mild Cognitive Impairment and Alzheimer's Disease , 2010, Alzheimer's & Dementia.

[48]  B. Winblad,et al.  Alzheimer's disease: clinical trials and drug development , 2010, The Lancet Neurology.

[49]  Judianne Davis,et al.  Structural conversion of neurotoxic amyloid-β(1–42) oligomers to fibrils , 2010, Nature Structural &Molecular Biology.

[50]  R. Maccioni,et al.  The revitalized tau hypothesis on Alzheimer's disease. , 2010, Archives of medical research.

[51]  D. Mann,et al.  Development of a proteolytically stable retro-inverso peptide inhibitor of beta-amyloid oligomerization as a potential novel treatment for Alzheimer's disease. , 2010, Biochemistry.

[52]  C. Rowe,et al.  Relationship between atrophy and β‐amyloid deposition in Alzheimer disease , 2010, Annals of neurology.

[53]  Alexander D. MacKerell,et al.  CHARMM general force field: A force field for drug‐like molecules compatible with the CHARMM all‐atom additive biological force fields , 2009, J. Comput. Chem..

[54]  R. Kirubagaran,et al.  Surfactant-induced conformational transition of amyloid β-peptide , 2009, European Biophysics Journal.

[55]  J. Gestwicki,et al.  Structure–activity Relationships of Amyloid Beta‐aggregation Inhibitors Based on Curcumin: Influence of Linker Length and Flexibility , 2007, Chemical biology & drug design.

[56]  D. Selkoe,et al.  Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide , 2007, Nature Reviews Molecular Cell Biology.

[57]  J. Gestwicki,et al.  Heat Shock Proteins 70 and 90 Inhibit Early Stages of Amyloid β-(1–42) Aggregation in Vitro* , 2006, Journal of Biological Chemistry.

[58]  Laxmikant V. Kalé,et al.  Scalable molecular dynamics with NAMD , 2005, J. Comput. Chem..

[59]  David Morgan,et al.  Green Tea Epigallocatechin-3-Gallate (EGCG) Modulates Amyloid Precursor Protein Cleavage and Reduces Cerebral Amyloidosis in Alzheimer Transgenic Mice , 2005, The Journal of Neuroscience.

[60]  Jianpeng Ma,et al.  Conformational transition of amyloid β-peptide , 2005 .

[61]  Jaehoon Yu,et al.  A hybrid molecule that prohibits amyloid fibrils and alleviates neuronal toxicity induced by beta-amyloid (1-42). , 2005, Biochemical and biophysical research communications.

[62]  M. Fändrich,et al.  FTIR reveals structural differences between native β‐sheet proteins and amyloid fibrils , 2004, Protein science : a publication of the Protein Society.

[63]  A. Miranker,et al.  Phospholipid catalysis of diabetic amyloid assembly. , 2004, Journal of molecular biology.

[64]  M. Mattson,et al.  Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.

[65]  A. D'Ursi,et al.  Solution structure of the Alzheimer amyloid beta-peptide (1-42) in an apolar microenvironment. Similarity with a virus fusion domain. , 2002, European journal of biochemistry.

[66]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[67]  W. Delano.  The PyMOL Molecular Graphics System , 2002 .

[68]  P. Damberg,et al.  Reversible Random Coil to β‐Sheet Transition and the Early Stage of Aggregation of the Aβ(12—28) Fragment from the Alzheimer Peptide. , 2000 .

[69]  A. Gräslund,et al.  Reversible Random Coil to β-Sheet Transition and the Early Stage of Aggregation of the Aβ(12−28) Fragment from the Alzheimer Peptide , 2000 .

[70]  Claudio Soto,et al.  β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy , 1998, Nature Medicine.

[71]  Alexander D. MacKerell,et al.  All-atom empirical potential for molecular modeling and dynamics studies of proteins. , 1998, The journal of physical chemistry. B.

[72]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[73]  R. Beavis,et al.  Fibrillogenesis of synthetic amyloid-β peptides is dependent on their initial secondary structure , 1995, Neuroscience Letters.

[74]  D. Brems,et al.  Secondary structure of amyloid beta peptide correlates with neurotoxic activity in vitro. , 1994, Molecular pharmacology.

[75]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[76]  Z. Khachaturian.  Diagnosis of Alzheimer's disease. , 1985, Archives of neurology.

[77]  William L. Jorgensen,et al.  Quantum and statistical mechanical studies of liquids. 25. Solvation and conformation of methanol in water , 1983 .

[78]  W. L. Jorgensen,et al.  Solvation and conformation of methanol in water , 1983 .